Globally, less than two-thirds of drug-resistant TB patients are successfully treated. With the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens. Civil society organisations have long called for greater access to short-course treatment regimens like BPaL and BPaLM. Its drug pretomanid received its first regulatory approval from the US Food and Drug Administration in 2019 as part of a six-month, all-oral regimen. About TB AllianceTB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB.
Continue reading...